Skip to main content

GHRS

Stock

GHRS

Stock
Health Care
Biotechnology

Performance overview

GHRS Price
Price Chart

Forward-looking statistics

Beta
0.81
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.

Company info

SectorHealth Care
IndustryBiotechnology
Employees29
Market cap$628.0M

Fundamentals

Enterprise value$465.4M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.79
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+4.1
Credit+5.4
Liquidity+0.5
Inflation-1.0
Commodities-0.7
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-12.97
Price to sales—
P/E Ratio-12.97
Enterprise Value to Revenue—
Price to book2.98

Upcoming events

Next earnings dayMay 3, 2024
Next dividend day—
Ex. dividend day—

News

What Makes GH Research (GHRS) a New Buy Stock

GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (May 5, 2025)
Why Is GH Research Stock Trading Higher On Monday?

On Monday, GH Research PLC GHRS said its Phase 2b trial with GH001, an inhalable bufotenin product candidate for treatment-resistant depression, met its primary endpoint.

Benzinga (February 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free